Deutsche Märkte schließen in 4 Stunden 25 Minuten

Lexicon Pharmaceuticals, Inc. (LXRX)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
1,5300-0,0900 (-5,56%)
Börsenschluss: 4:00PM EST

1,5300 0,00 (0,00 %)
Vorbörse: 7:00AM EST

Lexicon Pharmaceuticals, Inc.

8800 Technology Forest Place
The Woodlands, TX 77381-1160
United States
281 863 3000
http://www.lexpharma.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter184

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Lonnel CoatsPres, CEO & Director1,12MN/A1965
Mr. Jeffrey L. WadeExec. VP of Corp. & Admin. Affairs and CFO638,36kN/A1965
Dr. Praveen TyleExec. VP of R&D679,65kN/A1960
Dr. Robert J. LefkowitzConsultant & Independent Director44,64kN/A1944
Mr. James F. TessmerVP of Fin. & AccountingN/AN/A1960
Dr. Kimberly LeeHead of Investor Relations & Corp. StrategyN/AN/AN/A
Mr. Brian T. CrumVP, Gen. Counsel & Sec.N/AN/A1973
Chas SchultzExec. Director of Corp. Communications & Patient AdvocacyN/AN/AN/A
Dr. Alan J. MainExec. VP of Commercial Supply OperationsN/AN/A1954
Die Beträge haben den Stand 31. Dezember 2019 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabetes; LX9211, which is in Phase I clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Corporate Governance

Lexicon Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. November 2019, lautet 9. Die grundlegenden Scores sind Audit: 5, Vorstand: 9, Shareholderrechte: 7, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.